Brinker Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Brinker Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,051	Closed	-$360K	–	957
2019 Q2	$360K	Sell	5,051 -151	-3%	-$11.1K	0.01%	769
2019 Q1	$408K	Buy	5,202 +1,068	+26%	+$80.9K	0.02%	727
2018 Q4	$350K	Buy	4,134 +1,479	+56%	+$158K	0.02%	702
2018 Q3	$455K	Sell	2,655 -187	-7%	-$28.2K	0.02%	753
2018 Q2	$367K	Buy	2,842 +138	+5%	+$15.4K	0.01%	806
2018 Q1	$279K	Sell	2,704 -56	-2%	-$5.54K	0.01%	877
2017 Q4	$236K	Sell	2,760 -20	-0.7%	-$1.73K	0.01%	915
2017 Q3	$236K	Buy	+2,780	New	+$220K	0.01%	878
2017 Q2	–	Sell	-3,067	Closed	-$202K	–	780
2017 Q1	$202K	Buy	+3,067	New	+$202K	0.01%	884

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Brinker Capital's LGND Position: Q3 2019 in Review

Brinker Capital sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 5,051 shares — an estimated $360K sold.

Brinker Capital first reported a position in LGND in Q1 2017 and held it in 9 quarters. The position peaked at $455K in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Brinker Capital reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Brinker Capital sold 5,051 Ligand Pharmaceuticals shares in Q3 2019, an estimated $360K.
Brinker Capital first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 9 quarters.
Brinker Capital's Ligand Pharmaceuticals position peaked at $455K in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Brinker Capital's 13F filing for Q3 2019, filed 21 Oct 2019.